HERTHENA-Lung01: A phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC Review

  

Authors:	Yu, H. A.; Yang, J. C. H.; Hayashi, H.; Goto, Y.; Felip, E.; Reck, M.; Vigliotti, M.; Dong, Q.; Cantero, F.; Fan, P. D.; Kanai, M.; Sternberg, D. W.; Jänne, P. A.
Review Title:	HERTHENA-Lung01: A phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC
Journal Title:	Future Oncology
Volume:	19
Issue:	19
ISSN:	1479-6694
Publisher:	Future Medicine
Date Published:	2023-06-01
Start Page:	1319
End Page:	1329
Language:	English
DOI:	10.2217/fon-2022-1250
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
PUBMED:	37212796
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=cin20&AN=168589080&authtype=sso&custid=s2915669&site=ehost-live&scope=site&custid=s2915669
Notes:	Accession Number: 168589080 -- Entry Date: In Process -- Revision Date: 20230801 -- Publication Type: Article -- Journal Subset: Biomedical; Europe; UK & Ireland -- NLM UID: 101256629. -- Source: Cinahl

https://synapse.mskcc.org/synapse/works/has_related_data_chk/208569